RVNC - Revance Therapeutics, Inc.

QQQ $ 473.14 $ -2.10 (-0.44 %)

DIA $ 417.33 $ 2.44 (0.59 %)

SPY $ 562.48 $ 0.83 (0.15 %)

TLT $ 101.29 $ 0.92 (0.92 %)

GLD $ 238.61 $ -0.02 (-0.01 %)

Previous Close

$ 5.97

Open

Bid

$ 5.97 x 1,200

Ask

$ 6.57 x 1,200

Day's Range

-- - --

52 Week Range

$ 2.30 - $ 16.98

Volume

20,813,564

Average Volume

Market Cap

625.8M

Beta (5Y Monthly)

$ 1.41

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	02-25-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-06-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	02-26-2020	12-31-2019	10-K
20	11-04-2019	09-30-2019	10-Q
21	08-06-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-02-2018	09-30-2018	10-Q
25	08-03-2018	06-30-2018	10-Q
26	05-09-2018	03-31-2018	10-Q
27	03-02-2018	12-31-2017	10-K
28	11-03-2017	09-30-2017	10-Q
29	08-04-2017	06-30-2017	10-Q
30	05-09-2017	03-31-2017	10-Q
31	02-28-2017	12-31-2016	10-K
32	11-04-2016	09-30-2016	10-Q
33	08-05-2016	06-30-2016	10-Q
34	05-10-2016	03-31-2016	10-Q
35	03-04-2016	12-31-2015	10-K
36	11-10-2015	09-30-2015	10-Q
37	08-07-2015	06-30-2015	10-Q
38	05-14-2015	03-31-2015	10-Q
39	03-04-2015	12-31-2014	10-K
40	11-13-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Watching Revance Therapeutics; Shares Trad...
09/16/2024 19:54:48

Barclays Downgrades Revance Therapeutics t...
09/13/2024 19:46:10

Barclays analyst Balaji Prasad downgrades Revance Therapeutics (NASDAQ:RVNC) from Overweight to Equal-Weight and lowers the ...

Needham Downgrades Revance Therapeutics to...
08/13/2024 10:08:06

Needham analyst Serge Belanger downgrades Revance Therapeutics (NASDAQ:RVNC) from Buy to Hold.

Guggenheim Downgrades Revance Therapeutics...
08/12/2024 19:21:46

Guggenheim analyst Seamus Fernandez downgrades Revance Therapeutics (NASDAQ:RVNC) from Buy to Neutral.

gold-gains-over-1-starbucks-shares-move-higher

Gold Gains Over 1%; Starbucks Shares Move ...
08/12/2024 18:33:03

William Blair Downgrades Revance Therapeut...
08/12/2024 17:55:20

William Blair analyst Tim Lugo downgrades Revance Therapeutics (NASDAQ:RVNC) from Outperform to Market Perform.

crude-oil-surges-2-b-riley-financial-shares-plunge

Crude Oil Surges 2%; B. Riley Financial Sh...
08/12/2024 16:00:21

Botox Innovator Revance Therapeutics Goes ...
08/12/2024 15:50:55

Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.

ke-holdings-keycorp-revance-therapeutics-starbucks-and-other-big-stocks-moving-higher-on-monday

KE Holdings, KeyCorp, Revance Therapeutics...
08/12/2024 14:09:35

dow-dips-150-points-mondaycom-posts-upbeat-earnings

Dow Dips 150 Points; Monday.com Posts Upbe...
08/12/2024 13:49:15

Revance Therapeutics Shares Resumed Tradin...
08/12/2024 12:55:27

Trading Halt: Halt status updated at 8:25:...
08/12/2024 12:25:04

Crown Laboratories And Revance Therapeutic...
08/12/2024 12:02:41

Flagship Brands To Include DAXXIFY, RHA Collection, SkinPen, PanOxyl, Blue Lizard, And StriVectin; Merger Offers Global Commerc...

Trading Halt: Halted at 7:55:00 a.m. ET - ...
08/12/2024 11:55:04

Piper Sandler Maintains Overweight on Reva...
08/09/2024 14:05:33

Piper Sandler analyst David Amsellem maintains Revance Therapeutics (NASDAQ:RVNC) with a Overweight and lowers the price tar...

Stifel Maintains Buy on Revance Therapeuti...
08/09/2024 12:46:07

Stifel analyst Annabel Samimy maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $24 t...

Needham Reiterates Buy on Revance Therapeu...
08/09/2024 12:16:35

Needham analyst Serge Belanger reiterates Revance Therapeutics (NASDAQ:RVNC) with a Buy and maintains $12 price target.

Revance Therapeutics Sees FY24 Net Product...
08/08/2024 20:52:17

Revance Therapeutics Q2 2024 GAAP EPS $(0....
08/08/2024 20:17:46

Revance Therapeutics (NASDAQ:RVNC) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of ...

HC Wainwright & Co. Maintains Buy on Revan...
05/13/2024 16:37:41

HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price ta...